Kernal Biologics
Kernal combines T-cell-targeted LNP delivery with selective mRNA translation for in vivo CAR-T. Its ASGCT 2026 announcement concerns preclinical programming studies. An ARPA-H award supports development; it is research funding, not clinical validation or a venture financing round.
Corporate information
- Company entity
- Kernal Biologics
- Headquarters / principal office
- Cambridge, MassachusettsSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2016 ↗
- Ownership / capital status
- PrivatePrivately financed; disclosed Series A ↗
- Official corporate reference
- https://kernalbio.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2022-07-07 · Series A · US$25 million ↗
Verified historical financing, not confirmation of the latest financing. ARPA-H awards are research support and are not included as venture financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Kernal combines T-cell-targeted LNP delivery with selective mRNA translation for in vivo CAR-T. Its ASGCT 2026 announcement concerns preclinical programming studies. An ARPA-H award supports development; it is research funding, not clinical validation or a venture financing round.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Kernal Biologics — official company page
- Kernal company-issued Series A announcement — July 7, 2022
- Company-managed LinkedIn profile — self-reported location